世界の子宮内膜がん市場は、2023年に約151億米ドルに達すると推定され、2024年から2032年の予測期間には5.69%という高い年平均成長率（CAGR）で成長すると予想されています。子宮内膜がんは、主に子宮内膜に発生し、先進国において最も一般的な婦人科悪性腫瘍です。早期スクリーニング技術への意識の高まり、肥満率の上昇（主要な危険因子）、そしてホルモン補充療法へのアクセス拡大により、高度な診断および治療ソリューションの必要性が高まっています。精密腫瘍学および分子診断における革新は、医療提供者がこの疾患を検出、分類、そして管理する方法を急速に変革しており、特に介入が最も効果的な早期段階においてその傾向が顕著です。
特に第一選択のホルモン療法に抵抗性を示す患者における標的療法と免疫療法の需要の急増は、治療パラダイムを再構築する中核的な原動力の一つです。研究者や製薬会社は、より効果的な阻害薬、モノクローナル抗体、そして併用療法の開発に注力しています。同時に、子宮内膜生検や経膣超音波検査といった診断ツールは、非侵襲性と臨床的信頼性の高さから、広く普及しています。さらに、遺伝子バイオマーカーとコンパニオン診断の進歩により、腫瘍専門医は副作用を最小限に抑えながら患者の転帰を改善する治療戦略を個別に策定することが可能になっています。
こうした進歩にもかかわらず、世界の子宮内膜がん市場は、発展途上国における診断の遅れ、進行期または再発症例に対する治療選択肢の不足、医療アクセスの格差など、依然として大きな課題に直面しています。しかしながら、これらのギャップは、遠隔医療プラットフォームの拡大、世界的な腫瘍学啓発プログラム、臨床試験の普及拡大を目的とした国際的なパートナーシップを通じて、徐々に解消されつつあります。同時に、支援的な規制枠組みの整備により、画期的な医薬品やコンパニオン診断薬の市場承認が加速し、この分野への商業的関心がさらに高まっています。
地域別では、北アメリカが子宮内膜がん治療において圧倒的な地位を維持しており、これは強固な臨床インフラ、疾患スクリーニングの実施率の高さ、そして革新的な生物学的製剤の浸透によるものです。ヨーロッパは、女性の健康への投資の増加、集中治療プロトコル、そしてドイツ、イギリス、フランスといった主要経済国における規制当局の承認の急増に牽引され、これに追随しています。アジア太平洋地域は、医療サービスへのアクセス向上、がん啓発活動の活発化、そしてインド、中国、韓国といった急速に都市化が進む国々における生活習慣関連リスク要因の増加に支えられ、最も急速な成長が見込まれています。ラテンアメリカと中東・アフリカでは、各国政府が腫瘍学のケアと診断能力への投資を拡大していることから、緩やかな成長が見込まれています。
目次
Table of contents
Chapter 1. Global Endometrial Cancer Market Executive Summary
1.1. Global Endometrial Cancer Market Size & Forecast (2022 - 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Type of Cancer
1.3.2. By Type of Therapy
1.3.3. By Diagnosis Method
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Endometrial Cancer Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Endometrial Cancer Market Dynamics
3.1. Market Drivers
3.1.1. Rising Awareness of Early Screening and Diagnostic Techniques
3.1.2. Increasing Obesity Rates as a Key Risk Factor
3.1.3. Innovations in Precision Oncology and Molecular Diagnostics
3.2. Market Challenges
3.2.1. Delayed Diagnoses in Developing Nations
3.2.2. Limited Therapeutic Options for Late-Stage or Recurrent Disease
3.2.3. Disparities in Healthcare Access and Infrastructure
3.3. Market Opportunities
3.3.1. Surge in Demand for Targeted Therapy and Immunotherapy Regimens
3.3.2. Evolution of Genetic Biomarkers and Companion Diagnostics
3.3.3. Expansion of Telemedicine Platforms and Global Clinical Trial Partnerships
Chapter 4. Global Endometrial Cancer Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Endometrial Cancer Market Size & Forecasts by Type of Cancer (2022 - 2032)
5.1. Segment Dashboard
5.2. Endometrial Carcinoma: Revenue Trend Analysis, 2022 & 2032
5.3. Uterine Sarcomas: Revenue Trend Analysis, 2022 & 2032
Chapter 6. Global Endometrial Cancer Market Size & Forecasts by Type of Therapy (2022 - 2032)
6.1. Segment Dashboard
6.2. Chemotherapy: Revenue Trend Analysis, 2022 & 2032
6.3. Immunotherapy: Revenue Trend Analysis, 2022 & 2032
6.4. Hormonal Therapy: Revenue Trend Analysis, 2022 & 2032
6.5. Targeted Therapy: Revenue Trend Analysis, 2022 & 2032
6.6. Radiation Therapy: Revenue Trend Analysis, 2022 & 2032
6.7. Surgery: Revenue Trend Analysis, 2022 & 2032
Chapter 7. Global Endometrial Cancer Market Size & Forecasts by Diagnosis Method (2022 - 2032)
7.1. Segment Dashboard
7.2. Endometrial Biopsy: Revenue Trend Analysis, 2022 & 2032
7.3. Hysteroscopy: Revenue Trend Analysis, 2022 & 2032
7.4. Dilation and Curettage (D&C): Revenue Trend Analysis, 2022 & 2032
7.5. Transvaginal Ultrasound: Revenue Trend Analysis, 2022 & 2032
7.6. Others: Revenue Trend Analysis, 2022 & 2032
Chapter 8. Global Endometrial Cancer Market Size & Forecasts by Region (2022 - 2032)
8.1. North America Endometrial Cancer Market
8.1.1. U.S. Endometrial Cancer Market
8.1.1.1. By Type of Cancer, 2022 - 2032
8.1.1.2. By Type of Therapy, 2022 - 2032
8.1.1.3. By Diagnosis Method, 2022 - 2032
8.1.2. Canada Endometrial Cancer Market
8.2. Europe Endometrial Cancer Market
8.2.1. UK Endometrial Cancer Market
8.2.2. Germany Endometrial Cancer Market
8.2.3. France Endometrial Cancer Market
8.2.4. Spain Endometrial Cancer Market
8.2.5. Italy Endometrial Cancer Market
8.2.6. Rest of Europe Endometrial Cancer Market
8.3. Asia Pacific Endometrial Cancer Market
8.3.1. China Endometrial Cancer Market
8.3.2. India Endometrial Cancer Market
8.3.3. Japan Endometrial Cancer Market
8.3.4. Australia Endometrial Cancer Market
8.3.5. South Korea Endometrial Cancer Market
8.3.6. Rest of Asia Pacific Endometrial Cancer Market
8.4. Latin America Endometrial Cancer Market
8.4.1. Brazil Endometrial Cancer Market
8.4.2. Mexico Endometrial Cancer Market
8.4.3. Rest of Latin America Endometrial Cancer Market
8.5. Middle East & Africa Endometrial Cancer Market
8.5.1. Saudi Arabia Endometrial Cancer Market
8.5.2. South Africa Endometrial Cancer Market
8.5.3. Rest of Middle East & Africa Endometrial Cancer Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Pfizer Inc.
9.1.2. Novartis AG
9.1.3. Bristol-Myers Squibb Company
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Pfizer Inc.
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Novartis AG
9.3.3. Bristol-Myers Squibb Company
9.3.4. AstraZeneca PLC
9.3.5. F. Hoffmann-La Roche AG
9.3.6. Merck & Co., Inc.
9.3.7. Eisai Co., Ltd.
9.3.8. Eli Lilly and Company
9.3.9. GlaxoSmithKline plc
9.3.10. Amgen Inc.
9.3.11. Genentech, Inc.
9.3.12. Sanofi S.A.
9.3.13. Bayer AG
9.3.14. AbbVie Inc.
9.3.15. Teva Pharmaceutical Industries Ltd.
List of Tables
TABLE 1. Global Endometrial Cancer market, report scope
TABLE 2. Global Endometrial Cancer market estimates & forecasts by Region 2022-2032 (USD Million/Billion)
TABLE 3. Global Endometrial Cancer market estimates & forecasts by Type of Cancer 2022-2032 (USD Million/Billion)
TABLE 4. Global Endometrial Cancer market estimates & forecasts by Type of Therapy 2022-2032 (USD Million/Billion)
TABLE 5. Global Endometrial Cancer market estimates & forecasts by Diagnosis Method 2022-2032 (USD Million/Billion)
TABLE 6. Global Endometrial Cancer market by segment, estimates & forecasts, 2022-2032 (USD Million/Billion)
TABLE 7. Global Endometrial Cancer market by region, estimates & forecasts, 2022-2032 (USD Million/Billion)
TABLE 8. North America Endometrial Cancer market estimates & forecasts, 2022-2032 (USD Million/Billion)
TABLE 9. U.S. Endometrial Cancer market estimates & forecasts by segment 2022-2032 (USD Million/Billion)
TABLE 10. Canada Endometrial Cancer market estimates & forecasts by segment 2022-2032 (USD Million/Billion)
TABLE 11. Europe Endometrial Cancer market estimates & forecasts by country 2022-2032 (USD Million/Billion)
TABLE 12. Asia Pacific Endometrial Cancer market estimates & forecasts by country 2022-2032 (USD Million/Billion)
TABLE 13. Latin America Endometrial Cancer market estimates & forecasts by country 2022-2032 (USD Million/Billion)
TABLE 14. Middle East & Africa Endometrial Cancer market estimates & forecasts by country 2022-2032 (USD Million/Billion)
… (Additional tables continue through TABLE 20)
List of Figures
FIG 1. Global Endometrial Cancer market, research methodology
FIG 2. Global Endometrial Cancer market, market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global Endometrial Cancer market, key trends 2023
FIG 5. Global Endometrial Cancer market, growth prospects 2022-2032
FIG 6. Global Endometrial Cancer market, Porter’s 5 Force model
FIG 7. Global Endometrial Cancer market, PESTEL analysis
FIG 8. Global Endometrial Cancer market, value chain analysis
FIG 9. Global Endometrial Cancer market by segment, 2022 & 2032 (USD Million/Billion)
FIG 10. Global Endometrial Cancer market by region, snapshot 2022 & 2032
FIG 11. North America Endometrial Cancer market 2022 & 2032 (USD Million/Billion)
FIG 12. Europe Endometrial Cancer market 2022 & 2032 (USD Million/Billion)
FIG 13. Asia Pacific Endometrial Cancer market 2022 & 2032 (USD Million/Billion)
FIG 14. Latin America Endometrial Cancer market 2022 & 2032 (USD Million/Billion)
FIG 15. Middle East & Africa Endometrial Cancer market 2022 & 2032 (USD Million/Billion)
… (Additional figures continue through FIG 20)
End of Table of Contents
